anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Serious cases of hepatic injury have been observed in patients taking intravenous tocilizumab products. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation with tocilizumab products. While most cases presented with marked elevations of transaminases (> 5 times ULN), some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases.

During randomized controlled studies, treatment with tocilizumab was associated with a higher incidence of transaminase elevations [see Adverse Reactions (6.1, 6.3, 6.4)]. Increased frequency and magnitude of these elevations was observed when potentially hepatotoxic drugs (e.g., MTX) were used in combination with tocilizumab. 

For RA and GCA patients, obtain a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) before initiating TOFIDENCE, every 4 to 8 weeks after start of therapy for the first 6 months of treatment and every 3 months thereafter. It is not recommended to initiate TOFIDENCE treatment in RA or GCA patients with elevated transaminases ALT or AST greater than 1.5× ULN. In patients who develop elevated ALT or AST greater than 5× ULN, discontinue TOFIDENCE. For recommended modifications based upon increase in transaminases [see Dosage and Administration (2.8)]. 

Patients hospitalized with COVID-19 may have elevated ALT or AST levels. Multi-organ failure with involvement of the liver is recognized as a complication of severe COVID-19. The decision to administer TOFIDENCE should balance the potential benefit of treating COVID-19 against the potential risks of acute treatment with TOFIDENCE. It is not recommended to initiate TOFIDENCE treatment in COVID-19 patients with elevated ALT or AST above 10 × ULN. Monitor ALT and AST during treatment.

Measure liver tests promptly in patients who report symptoms that may indicate liver injury, such as fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have abnormal liver tests (e.g., ALT greater than three times the upper limit of the reference range, serum total bilirubin greater than two times the upper limit of the reference range), TOFIDENCE treatment should be interrupted and investigation done to establish the probable cause. TOFIDENCE should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests.

A similar pattern of liver enzyme elevation is noted with tocilizumab products treatment in the PJIA and SJIA populations. Monitor liver test panel at the time of the second administration and thereafter every 4 to 8 weeks for PJIA and every 2 to 4 weeks for SJIA.
BACKGROUND: Longitudinal data in health informatics studies often present challenges due to sparse observations from each subject, limiting the application of contemporary deep learning for prediction. This issue is particularly relevant in predicting birthweight, a crucial factor in identifying conditions such as macrosomia and large-for-gestational age (LGA). Previous approaches have relied on empirical formulas for estimated fetal weights (EFWs) from ultrasound measurements and mixed-effects models for interim predictions.
METHOD: The proposed novel supervised longitudinal learning procedure features a three-step approach. First, EFWs are generated using empirical formulas from ultrasound measurements. Second, nonlinear mixed-effects models are applied to create augmented sequences of EFWs, spanning daily gestational timepoints. This augmentation transforms sparse longitudinal data into a dense parallel sequence suitable for training recurrent neural networks (RNNs). A tailored RNN architecture is then devised to incorporate the augmented sequential EFWs along with non-sequential maternal characteristics.
RESULTS: The RNNs are trained on augmented data to predict birthweights, which are further classified for macrosomia and LGA. Application of this supervised longitudinal learning procedure to the Successive Small-for-Gestational-Age Births study yields improved performance in classification metrics. Specifically, sensitivity, area under the receiver operation characteristic curve, and Youden's Index demonstrate enhanced results, indicating the effectiveness of the proposed approach in overcoming sparsity challenges in longitudinal health informatics data.
CONCLUSIONS: The integration of mixed-effects models for temporal data augmentation and RNNs on augmented sequences shows effective in accurately predicting birthweights, particularly in the context of identifying excessive fetal growth conditions.
Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
This research sought to delineate risk factors associated with surgical site infections (SSIs) post-total knee arthroplasty (post-TKA) in elderly osteoarthritis patients, aiming to enhance post-surgical outcomes. A retrospective examination was conducted on a cohort of 650 elderly patients who underwent unilateral TKA between January 2018 and August 2022. Data procurement was from the hospital's Electronic Health Record, and a comprehensive statistical evaluation was performed using IBM SPSS Statistics version 24.0. Both univariate and multivariate techniques assessed a spectrum of risk determinants such as age, body mass index (BMI), coexisting medical conditions and surgical variables. The univariate examination spotlighted age, BMI, diabetes prevalence, chronic corticosteroid consumption and American Society of Anesthesiologists (ASA) physical status classification as notable predictors of SSIs. The multivariate logistic regression pinpointed age, BMI, history of smoking and diabetes diagnosis as salient risk attributors for post-TKA infections. Concurrently, parameters like ASA classification, surgical duration and intraoperative haemorrhage further enriched the risk landscape. Geriatric patients undergoing TKA for knee osteoarthritis manifest a tangible infection susceptibility post-surgery. Precision interventions concentrating on amendable risk components, including meticulous preoperative evaluations and strategic postoperative care, are imperative to attenuate SSI incidence, thereby amplifying surgical efficacy and optimizing patient recuperation trajectories.
INTRODUCTION: Wearable cardioverter-defibrillators (WCD) have emerged as a valuable tool in the management of patients at risk for life-threatening arrhythmias. These devices offer a non-invasive and temporary solution, providing continuous monitoring and the potential for prompt defibrillation when needed. In this study, we explore the use of WCD and evaluate arrhythmic events through comprehensive monitoring.
METHODS: From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Regular check-ups, remote monitoring and comprehensive echocardiography were performed to optimise a tailored therapy.
RESULTS: The average age of the patients was 59.2.4±16.5 years, with 78% being male. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. WCD was assigned according to the Italian Association of Hospital Cardiologists position paper focussing on the appropriate use of WCD and European Society of Cardiology guidelines on ventricular arrhythmias and the prevention of sudden cardiac death: 24 (58%) patients had a de novo diagnosis of heart failure with reduced ejection fraction, 11 (27%) patients had a recent acute coronary syndrome and ejection fraction <35%, 3 (7%) patients had a cardiac electronic device extraction and 3 (7%) patients had myocarditis with features of electrical instability. The average follow-up was 62±38 days according to specific aetiology, with a daily wearing time of 22.7±1.3 hours. No device interventions were recorded. At the end of the follow-up period, 15 patients still required an implantable cardioverter-defibrillator (ICD). Among these, 12 patients (29%) underwent ICD implantation. Two patients (5%) declined the procedure.
CONCLUSIONS: The use of WCD for patients at high risk of arrhythmias allowed to optimise therapy and limit the indications for ICD. Inappropriate implantation of ICD was avoided in 69% of patients who received WCD. The device showed a good safety profile, low incidence of device interventions and adequate patients' adherence to WCD use.
The invention provides a compound traditional Chinese medicinal pill for treating bloody stool of pets, and a preparation method thereof. The pill is composed of 60g of Rhizoma Coptidis and 60g of Fructus Aurantii (120g of sophora flower is simultaneously stir-fried and then is removed). Effective components of the above medicines are respectively extracted through a certain technology. Rhizoma Coptidis is minced, and obtained steamed cakes are processed to obtain the pill. The method is simple and reasonable, and allows the pill with convenient use and long period of validity to be obtained. The pill has good curative effect and wide indication, is safe, effective and stable to pets, and can be conveniently used by the pets.
An automated system for organizing, presenting, and manipulating medical images includes a database in which the medical images are structured into groups, each group including one or more image series, each image series including an ordered sequence of images which illustrate incrementally registered aspects of an anatomical target. Image series are presented in their sequential order either in a monitor presentation format which displays each sequence in its entirety in a single monitor display container or which presents two or more image series, image-by-image, in adjacent presentation areas of a series display container. The system includes a plurality of monitors in which all monitors, save one, produce display containers for image series presentation. One monitor is reserved for displaying a working palette to which images of the image series displayed on the other monitors may be moved. The system activates a monitor in a plurality of monitors in response to movement of a cursor between monitors. An active monitor is indicated by presentation of a control panel. The system also provides heads-up presentation of control panel icons at a cursor location outside of the control panel by sequentially changing the shape of the cursor to the icon shapes for user selection.
The method and system may quantify how much contrast fluid is injected into a patient by a powered fluid injector. A controller of the powered fluid injector may receive a command from a user to begin administering contrast fluid. The controller may determine whether a hemodynamic pressure signal is present at a pressure sensor fluidly connected to the vasculature of the patient. The powered fluid injector may deliver an amount of contrast fluid in response to a command. The controller may add an amount of contrast fluid to the injection volume if a hemodynamic pressure signal is present just before and/or just after the administration of the amount of contrast fluid. The controller may refrain from adding an amount of contrast fluid to the injected volume if a hemodynamic pressure signal is not present just before and/or after administering the amount of contrast fluid.
BACKGROUND: The aim of this registry study was to evaluate the efficacy of Pycnogenol® in controlling signs/symptoms and temporary impairment of cognitive function (COFU) associated with jet lag. Previous flight studies have shown a decrease in the level of jet lag symptoms with Pycnogenol®. The control of jet lag signs/symptoms appeared to be correlated with flight-related microangiopathy and peripheral edema. Pycnogenol® - a standardized extract from the bark of French maritime pine - has significant antiedema, anti-inflammatory and antioxidant properties.
METHODS: A group of subjects flying east in economy class for 10-12 hours used Pycnogenol® 150 mg/day and a similar group without supplementation served as controls. A subgroup of mild hypertensive subjects using a single ACE inhibitor was also included.
RESULTS: One hundred twenty-seven subjects completed the study. Of the participants, 48 were aviation professionals like pilots, flight attendants or air company staff - 24 of them took Pycnogenol® and 24 served as controls. Forty-seven study participants were frequent flyers and non-staff professionals, 25 of which took Pycnogenol® and 22 served as controls. In addition, a group of 32 subjects with mild hypertension was included, 16 took Pycnogenol® and 16 served as controls. No side effects and a good tolerability were observed. The registry groups were comparable for baseline characteristics. Eastbound flights' duration was 11.22±0.4 hours in supplemented subjects and 11.14±0.32 in controls. Dropouts were due to logistical problems. Post flight Visual Analogue Scale (VAS) scores were significantly lower in all Pycnogenol® groups, including hypertensives for all signs and symptoms of jet lag compared to controls, showing prevention and improvement of jet lag symptoms. The duration of any sign/symptom of jet lag with Pycnogenol® intake was significantly shorter (P<0.05) post-flight compared to controls (P<0.05). The number of nights of altered/disturbed sleep was also lower in the Pycnogenol® groups compared to controls. Leg edema was present in almost all subjects with different degrees especially in the hypertensive group. The increase in ankle circumference before and after flight was significantly lower with Pycnogenol® compared to controls (P<0.05). After the flight, average scores of the single COFU tasks were significantly higher in the Pycnogenol® groups compared to controls, showing preserved cognitive function.
CONCLUSIONS: In conclusion, in this registry study Pycnogenol® was effective in preventing jet lag-related symptoms and preserving cognitive functions without tolerability problems. These observations should be tested in a larger group of subjects including complex individuals prone to edema (i.e. diabetics, hypertensive or older patients).
AIM: Dermaseptins are one of the main families of antimicrobial peptides (AMPs) derived from the skin secretions of Hylidae frogs. Among them, dermaseptin S4 (DS4) is characterized by its broad-spectrum of activity against bacteria, protozoa, and fungi. In this study, the physicochemical properties of the native peptide DS4 (1-28) and two derivatives [DS4 (1-28)a and DS4 (1-26)a] isolated from the skin of the frog Phyllomedusa sauvagii were investigated and their antimicrobial properties against two marine pathogenic bacteria (Vibrio harveyi and Vibrio anguillarum) were examined.
METHODS AND RESULTS: The results indicate that the peptide DS4 (1-26)a has high-antibacterial activity against the tested strains and low-hemolytic activity (<30% lysis at the highest tested concentration of 100 µg/mL) compared to the other two peptides tested. In addition, all three peptides affect the membrane and cell wall integrity of both pathogenic bacteria, causing leakage of cell contents, with DS4 (1-26)a having the most severe impact. These skills were corroborated by transmission electron microscopy and by the variation of cations in their binding sites due to the effects caused by the AMPs.
CONCLUSIONS: These results suggest that DS4 and its derivatives, in particular the truncated and amidated peptide DS4 (1-26)a could be effective in the treatment of infections caused by these marine pathogenic bacteria. Future studies are required to validate the use of DS4  in vivo for the prevention of bacterial diseases in fish.
This study involves a comparison of two different regimens of prostaglandin use for "cervical ripening" prior to induction of labor. Women admitted to the hospital for induction of labor who are found to have "unripe" cervixes at the time of admission, and who agree to participate in the study will be randomly assigned to one of two treatment groups. In one group, a single dose of 25 µcg of misoprostol will be administered vaginally and four hours later oxytocin induction will be started if clinically indicated. In the second group of women, repeat doses of misoprostol will be given every four hours up to six doses unless labor or cervical ripening occurs sooner. At this point, oxytocin will be started as needed. Success of vaginal delivery by 24 hours, time from initiation of protocol to delivery and cesarean section rates will be compared. Complications such as postpartum hemorrhage, episodes of tachysystole with fetal compromise and chorioamnionitis and endometritis will be monitored.
The invention relates to a Chinese medicinal preparation for treating livestock dysentery, in particular to a specific medicament for treating dysentery of dogs. The Chinese medicinal preparation comprises the following raw material medicaments in part by weight: 10 to 60 parts of parslane herb, 10 to 30 parts of Chinese pulsatilla root, 10 to 20 parts of golden thread, 10 to 20 parts of ash bark and 10 to 15 parts of costustoot. The Chinese medicinal preparation is prepared by grinding the medicaments by a grinder, passing the powders through 100-mesh sieve and packaging the powders. The Chinese medicinal preparation has the usage and the dosage that the preparation can be taken orally, or can be made into bolus, or can be taken by decoction, and the Chinese medicinal preparation can be taken appropriately according to different livestocks and weights of the livestocks. Besides the effect of the general veterinary medicaments for treating the ordinary diarrhea of the livestocks, the Chinese medicinal preparation particularly has the excellent effect of treating the diarrhea of the dogs which cannot be solved by the prior art. The Chinese medicinal preparation has the advantages of low cost, wide range of medicament sources, simple preparation process, quick diarrhea stopping, short course of treatment, good treatment effect, no toxic or side effect and the like.
PURPOSE: An aqueous insulin preparation comprising human insulin, an analog or derivative thereof is provided which improves chemical stability thereof. CONSTITUTION: An insulin preparation having superior chemical stability is prepared in the presence of glycerol and/or mannitol, and low concentration in particular, 5-100 mM, preferably, 5-40 mM of halogenide. Especially, in low concentration of halogenide, its physical stability can't not be denatured. Wherein, halogenide is preferably, alkaly, or alkalyto compounds and more preferably, chlorides such as sodium chloride. The concentration of glycerol and/or mannitol is 100-250 mM, more desirably, 140-250 mM and most desirably, 160-200 mM. Optionally, the preparation comprises phosphoric acid and citric acid and formulated for non oral administration.
BACKGROUND: Personalised Care and Support Planning (PCSP) replaces conventional annual reviews for people with long-term conditions. It is designed to help healthcare professionals (HCPs) and patients engage in conversations as equals and collaboratively plan actions oriented to each patient's priorities, alongside biomedical concerns. Little is known about how the shift to remote consulting initiated with COVID-19 restrictions has impacted PCSP.
AIM: To investigate HCPs' experiences of conducting PCSP conversations remotely and consider implications for the fulfilment of PCSP ambitions as remote consulting continues beyond COVID-19 restrictions.
METHODS: 19 semi-structured interviews with HCPs in England and Scotland; interpretive analysis.
RESULTS: HCPs' accounts made clear that COVID-19 restrictions impacted multiple aspects of PCSP delivery, not just the mode of conversation. Broader disruption to general practice systems for gathering and sharing information ahead of PCSP conversations, and moves to 'wide window' appointment times, made it harder for patients to be prepared for PCSP conversations. This constrained scope to achieve PCSP ambitions even with the best professional communication skills. Most remote PCSP conversations were conducted by telephone. In the absence of visual communication with patients, it was sometimes harder to achieve the ambitions of PCSP conversations, including to balance patient and professional agendas, fulfil key planning activities, and foster a relational ethos of equal, collaborative partnership. The challenges were particularly severe when working with new patients and people with complex clinical and social problems. Although options for telephone appointments now offer valued flexibility, sustained experience of struggling to achieve PCSP ambitions via remote consulting led some HCPs to lower their standards for judging a "good" PCSP conversation, and to diminished professional satisfaction.
CONCLUSIONS: There are significant challenges to fulfilling the ambitions of PCSP via telephone, especially when preparatory support is limited. This study provides grounds for scepticism about how compatible telephone appointments can be with this person-centred model of working, especially for people who are socially disadvantaged and live with complex health conditions. These threats to the provision of person-centred support for people with long-term conditions warrant careful attention going forward if the PCSP model and its benefits are to be sustained.
IVH is one of the most common complications in preterm infants. Nearly 60% of preterm infants with grade III-IV IVH develop severe neurodevelopmental outcomes. There are currently no effective treatments to prevent preterm infants with IVH from developing ventricular dilation or serious neurological disabilities. Recent studies have shown that EPO could improve neurodevelopmental outcomes in preterm infants with grade III-IV IVH. However, the dose and course of EPO in preterm infants is still uncertain. The purpose of the study was whether repeated low-dose EPO (500 U/kg, every other day, for 2 weeks) given to very preterm right after the diagnosis of IVH could improve long-term neurological outcomes. Very preterm infants with gestational age of ≤ 32 weeks who are diagnosed with IVH within 72 hours after birth in NICU are eligible for enrolment. After informed consent is obtained, infants will be randomly assigned to EPO group or vehicle group. The primary outcome is whether EPO improves mortality and neurological disabilities in very preterm infants with IVH at 18 months of corrected age, and the secondary outcome was whether EPO decrease the incidence of cerebral palsy, MDI\<70, blindness, and deafness.
Participants do not receive text messages during Interval 2. Participants receive attention control text messages during Interval 3.